In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on GeoVax Labs (GOVX – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $2.15.
LeBoyer covers the Healthcare sector, focusing on stocks such as GeoVax Labs, Ocugen, and PDS Biotechnology. According to TipRanks, LeBoyer has an average return of -10.4% and a 25.50% success rate on recommended stocks.
GeoVax Labs has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $11.86 and a one-year low of $2.04. Currently, GeoVax Labs has an average volume of 40.1K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GOVX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GeoVax Labs (GOVX) Company Description:
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.
Read More on GOVX:
